Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Myeloproliferative neoplasms (incl. CML)
Trial Type:  Treatment
Results 1-25 of 168 for your search:
Start Over
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Phase: Phase IV
Type: Treatment
Age: Not specified
Trial IDs: CAMN107A2409, NCI-2013-02332, 2012-003902-28, NCT01735955
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
PEG-Interferon Alfa-2a or Hydroxyurea in Treating Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MPD-RC 112, NCI-2012-00269, NCT01259856
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116428, NCI-2014-01414, 2012-003438-18, NCT01767467
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PERSIST-2 (PAC326), NCI-2014-00893, NCT02055781
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-352-0101, NCI-2013-02398, 2013-002707-33, NCT01969838
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Busulfan, Fludarabine Phosphate, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: HEM-05011-L, NCI-2013-00779, CDR0000447204, OHSU-210, OHSU-HEM-05011-L, NCT00245037
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 70
Trial IDs: 2005-0781, NCI-2011-02823, RP100469 02, NCT00498316
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OV06-001, NCI-2010-00051, NCT00709215
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KB004-01, NCI-2011-00883, NCT01211691
Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide after Donor Bone Marrow Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 6 months to 85
Trial IDs: J1151, NCI-2014-01339, CR00000875, NA_00048378, NA_00048378 / CIR00006178, NCI-2014-00310, NCT01342289
Donor Cytokine-Induced Killer Cells in Treating Patients with Myelodysplasia or Myeloproliferative Disorders Previously Treated with Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 50 and over
Trial IDs: BMT217, NCI-2011-01493, SU-04202010-5724, NCT01392989
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 201112026, NCI-2014-01309, NCI-2011-02328, POL-4, NCT01413568
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NS-018-101, NCI-2011-03576, NCT01423851
Dasatinib and Decitabine in Treating Patients with Accelerated or Blastic Phase Chronic Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0333, NCI-2012-00014, CA180357, NCT01498445
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PRI-724-201, NCI-2012-01153, NCT01606579
Laboratory-Treated T Cells in Treating Patients with High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated with Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2498.00, NCI-2011-03362, NCT01640301
Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-180-384, NCI-2012-00773, 2011-204, NCT01643603
Start Over